Patient-derived tumour xenografts as models for oncology drug development

Long-Term Engraftment and Expansion of Tumor-Derived Memory T Cells Following the Implantation of Non-Disrupted Pieces of Human Lung Tumor into NOD-scid IL2R null Mice

(2014) M. R. Simpson-Abelson et al.   JOURNAL OF IMMUNOLOGY

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials

(2011) Chris Coppin et al.   BJU INTERNATIONAL

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model

(2011) J S P Yuen et al.   BRITISH JOURNAL OF CANCER

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

(2011) T. Sasaki et al.   CANCER RESEARCH

Tumor Engraftment in Nude Mice and Enrichment in Stroma- Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer

(2011) I. Garrido-Laguna et al.   CLINICAL CANCER RESEARCH

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

(2011) N. V. Rajeshkumar et al.   CLINICAL CANCER RESEARCH

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance

(2011) Rebekka Krumbach et al.   EUROPEAN JOURNAL OF CANCER

Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?

(2011) Johannes Merk et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

(2011) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients

(2011) Chiara Grisanzio et al.   JOURNAL OF PATHOLOGY

Vascular Disruption in Combination with mTOR Inhibition in Renal Cell Carcinoma

(2011) L. Ellis et al.   MOLECULAR CANCER THERAPEUTICS

Proof of Principle for Crizotinib in Anaplastic Lymphoma Kinase-Positive Malignancies Was Achieved in ALK-Positive Nonclinical Models

(2011) J. G. Christensen   MOLECULAR CANCER THERAPEUTICS

A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer

(2011) M. Hidalgo et al.   MOLECULAR CANCER THERAPEUTICS

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

(2011) Yoko S DeRose et al.   NATURE MEDICINE

Promoter Methylation in Head and Neck Squamous Cell Carcinoma Cell Lines Is Significantly Different than Methylation in Primary Tumors and Xenografts

(2011) Patrick T. Hennessey et al.   PLoS One

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

(2011) Olivier Keunen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1

(2011) N. Agrawal et al.   SCIENCE

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

(2011) N. Stransky et al.   SCIENCE

A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

(2011) A. Bertotti et al.   Cancer Discovery

Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study

(2011) Jenni K Peltonen et al.   Head and Neck Optical Diagnostics Society

A reproducible brain tumour model established from human glioblastoma biopsies

(2010) Jian Wang et al.   BMC CANCER

Cryopreservation of human colorectal carcinomas prior to xenografting

(2010) Michael Linnebacher et al.   BMC CANCER

Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models

(2010) Siver A Moestue et al.   BMC CANCER

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer

(2010) I Garrido-Laguna et al.   BRITISH JOURNAL OF CANCER

Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation

(2010) L de Plater et al.   BRITISH JOURNAL OF CANCER

Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review

(2010) Ketao Jin et al.   Clinical & Translational Oncology

Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non-Small Cell Lung Cancer

(2010) S. Hammer et al.   CLINICAL CANCER RESEARCH

Gene Array and Fluorescence In situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer

(2010) J. J. Arcaroli et al.   CLINICAL CANCER RESEARCH

Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors

(2010) F. Nemati et al.   CLINICAL CANCER RESEARCH

Patient-Derived First Generation Xenografts of Non-Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy

(2010) X. Dong et al.   CLINICAL CANCER RESEARCH

Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line-Derived Human Colorectal Cancer Xenograft Models

(2010) J. J. Tentler et al.   CLINICAL CANCER RESEARCH

Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development

(2010) T. M. Pitts et al.   CLINICAL CANCER RESEARCH

The Ability to Form Primary Tumor Xenografts Is Predictive of Increased Risk of Disease Recurrence in Early-Stage Non-Small Cell Lung Cancer

(2010) T. John et al.   CLINICAL CANCER RESEARCH

Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study

(2010) H. J. Hammers et al.   MOLECULAR CANCER THERAPEUTICS

Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer

(2010) M. C. Villarroel et al.   MOLECULAR CANCER THERAPEUTICS

Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras-Mutated Colorectal Cancer

(2010) J. J. Tentler et al.   MOLECULAR CANCER THERAPEUTICS

A Fine-Needle Aspirate-Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer

(2010) A. Jimeno et al.   MOLECULAR CANCER THERAPEUTICS

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

(2010) Mallika Singh et al.   NATURE BIOTECHNOLOGY

A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo

(2010) L. Yu et al.   NEURO-ONCOLOGY

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

(2010) D Ercan et al.   ONCOGENE

Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts

(2009) Fariba Némati et al.   ANTI-CANCER DRUGS

Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney

(2009) R. Beroukhim et al.   CANCER RESEARCH

A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture In vitro

(2009) V. C. Daniel et al.   CANCER RESEARCH

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification

(2009) Takeshi Yoshida et al.   CANCER SCIENCE

Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer

(2009) N.V. Rajeshkumar et al.   CLINICAL CANCER RESEARCH

Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?☆

(2009) Johannes Merk et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts

(2009) W. A. Messersmith et al.   MOLECULAR CANCER THERAPEUTICS

Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice

(2009) Michael P Kim et al.   Nature Protocols

Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene

(2009) S. Jones et al.   SCIENCE

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer

(2008) A. Jimeno et al.   CANCER RESEARCH

Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma

(2008) H. Huynh et al.   CLINICAL CANCER RESEARCH

Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers

(2008) I. Fichtner et al.   CLINICAL CANCER RESEARCH

Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer

(2008) J. M. Bailey et al.   CLINICAL CANCER RESEARCH

Direct In Vivo Xenograft Tumor Model for Predicting Chemotherapeutic Drug Response in Cancer Patients

(2008) B Rubio-Viqueira et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Differential transplantability of human endothelial cells in colorectal cancer and renal cell carcinoma primary xenografts

(2008) Laura Sanz et al.   LABORATORY INVESTIGATION

Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer

(2008) Dongweon Song et al.   MOLECULAR CANCER THERAPEUTICS

Identification of cells initiating human melanomas

(2008) Tobias Schatton et al.   NATURE

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE